| Friday, January 8 |
|
3:00 - 7:30 PM
|
Registration
|
Matterhorn Foyer
|
|
6:30 - 7:30 PM
|
Refreshments
|
Matterhorn Foyer
|
|
7:30 - 8:30 PM
|
Keynote Address
|
Matterhorn Ballroom
|
|
|
|
|
Napoleone Ferrara,
Genentech, Inc.
The Avastin Story: Challenges and Lessons
|
|
| Saturday, January 9 |
|
7:00 - 8:00 AM
|
Breakfast
|
Schneitter's
|
|
8:00 - 11:00 AM
|
Antibody Discovery and Engineering
|
Matterhorn Ballroom
|
|
|
|
|
Matthew Sleeman,
MedImmune
Antibody Structure Function Relationships
|
|
|
Tillman U. Gerngross,
Dartmouth College and CEO and Co-founder of Adimab
Adimab’s Novel Human Antibody Discovery Platform: A New Benchmark for Antibody Discovery Technologies
|
|
|
John R. Desjarlais,
Xencor
Creating Novel and Enhanced Antibody Therapeutics through Fc Engineering
|
|
|
James A. Van Deventer,
California Institute of Technology
Short Talk: Antibody Fragment Engineering With Non-Canonical Amino Acids
|
|
|
11:00 AM -
|
On Own for Lunch and Recreation
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Matterhorn Foyer
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Matterhorn Foyer
|
|
5:00 - 7:00 PM
|
Protein and Peptide Engineering
|
Matterhorn Ballroom
|
|
W. David Shen,
Merck & Co., Inc.
From Mammalian Cell Display to Cross-Species Display of Antibodies
|
|
|
|
|
|
Clark Pan,
Genzyme Corporation
Carbohydrate Engineering of Acid alpha-Glucosidase for Treatment of Pompe Disease
|
|
|
David V. Liu,
Massachusetts Institute of Technology
Short Talk: Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Grindelwald/Davos
|
| Sunday, January 10 |
|
7:00 - 8:00 AM
|
Breakfast
|
Schneitter's
|
|
8:00 - 11:00 AM
|
Next Generation Protein-Based Biopharmaceuticals
|
Matterhorn Ballroom
|
|
|
|
|
Volker Schellenberger,
Amunix Inc.
Protein Pharmaceuticals Comprising an XTEN Half-Life Extension Module
|
|
|
Richard J.M. Ross,
University of Sheffield
Hormone/Hormone Receptor Fusion Proteins for Improving the Pharmacokinetic/Pharmacodynamic Properties of Hormone Replacement Therapies
|
|
|
Peter D. Senter,
Seattle Genetics Inc.
Antibody-Drug Conjugates for Cancer Therapy
|
|
|
Chengbin Wu,
Abbott Bioresearch Center
Protein Engineering of DVD-Ig: Focusing on Pharmacokinetics, Manufacturing, and Preformulation Studies
|
|
|
Bernd J. Wranik,
Genentech
Short Talk: LUZ-Y: An Engineered Antibody Format for the Production of One-Armed and Bispecific Antibodies in Mammalian (CHO) Cells
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Matterhorn Foyer
|
|
11:00 AM - 1:00 PM
|
Poster Setup
|
Grindelwald/Davos
|
|
11:00 AM -
|
On Own for Lunch and Recreation
|
|
|
1:00 - 10:00 PM
|
Poster Viewing
|
Grindelwald/Davos
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Matterhorn Foyer
|
|
5:00 - 7:00 PM
|
Nucleic Acid-Based Biopharmaceuticals
|
Matterhorn Ballroom
|
|
James M. Wilson,
University of Pennsylvania
Gene Therapy: Lessons Learned and Opportunities for the Future
|
|
|
C. Frank Bennett,
ISIS Pharmaceuticals, Inc.
Progress in Antisense Therapeutics
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dinah Sah,
Alnylam Pharmaceuticals, Inc.
Development of RNAi Therapeutics
|
|
|
Pengbo Zhou,
Weill Cornell Medical College
Short Talk: Integration of RNAi and Protein Knockout Technology for Efficient Eradication of Cellular Proteins
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Grindelwald/Davos
|
|
7:30 - 10:00 PM
|
Poster Session 1
|
Grindelwald/Davos
|
| Monday, January 11 |
|
7:00 - 8:00 AM
|
Breakfast
|
Schneitter's
|
|
8:00 - 11:00 AM
|
Cancer and Cancer Supportive Care
|
Matterhorn Ballroom
|
|
Michael Reiss,
Robert Wood Johnson Medical School
TGF-beta as a New Cancer Therapy Target
|
|
|
Elisabeth G.E. de Vries,
Universitair Medisch Centrum Groningen
Use of Zirconium-89 Labeled Antibodies for Tumor Imaging: Possible Applications for Guiding Targeted Tumor Therapy
|
|
|
|
|
|
Patrick A. Baeuerle,
Micromet, Inc.
Cancer Therapy by T Cell-Engaging BiTE Antibodies
|
|
|
|
|
|
Antonio Gualberto,
Pfizer Oncology
Development of Figitumumab (CP-751,871), a Fully Human Monoclonal Antibody against the IGF-1R
|
|
|
John C. Zwaagstra,
Biotechnology Research Institute NRCC
Short Talk: Design and Efficacy of Single-Chain Traps Targeting Ligands of the Transforming Growth Factor-beta (TGF-beta) Family: The New Generation of Cancer Therapeutics/Diagnostics
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Matterhorn Foyer
|
|
11:00 AM -
|
On Own for Lunch and Recreation
|
|
|
1:00 - 10:00 PM
|
Poster Viewing
|
Grindelwald/Davos
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Matterhorn Foyer
|
|
5:00 - 7:00 PM
|
Immune-Mediated Diseases/Transplant
|
Matterhorn Ballroom
|
|
C. Randal Mills,
Osiris Therapeutics, Inc.
Mesenchymal Stem Cells for Treatment of GVHD
|
|
|
Alasdair Coles,
University of Cambridge
Anti-CD52 Antibodies for the Treatment of Multiple Sclerosis
|
|
|
Kristine Kikly,
Eli Lilly and Company
Anti-BAFF for the Treatment of Rheumatoid Arthritis
|
|
|
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Grindelwald/Davos
|
|
7:30 - 10:00 PM
|
Poster Session Viewing
|
Grindelwald/Davos
|
| Tuesday, January 12 |
|
7:00 - 8:00 AM
|
Breakfast
|
Schneitter's
|
|
8:00 - 11:00 AM
|
Diabetes
|
Matterhorn Ballroom
|
|
|
|
|
Bart Keymeulen,
Vrije Universiteit Brussel
Preservation of Beta Cell Function in Human Type 1 Diabetes
|
|
|
Sushil G. Rane,
National Institutes of Health
Protection from Obesity and Diabetes by Blockade of TGF-beta/Smad3 Signaling
|
|
|
|
|
|
Alexei Kharitonenkov,
Eli Lilly and Company
FGF-21 and its Novel Variants to Treat Metabolic Disorders
|
|
|
Lucienne Chatenoud,
INSERM, Hopital Necker
Restoration of Self Tolerance in Autoimmune Diabetes
|
|
|
|
|
|
Biju Parekkadan,
Massachusetts General Hospital, Harvard Medical School
Short Talk: Natural Therapeutics Derived from the Bone Marrow Stroma
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Matterhorn Foyer
|
|
11:00 AM -
|
On Own for Lunch and Recreation
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Matterhorn Foyer
|
|
5:00 - 7:00 PM
|
Metabolic and Neurological Disorders
|
Matterhorn Ballroom
|
|
|
|
|
Ronald B. DeMattos,
Lilly Research Laboratories
Abeta Immunotherapy: The Development of Compound Specific Biomarkers to Aid the Translation of Preclinical to Clinical Studies
|
|
|
Mike Ominsky,
Amgen Inc.
OPG/RANKL and Sclerostin; Physiological Regulators of Bone Density; Targets for the Treatment of Bone Loss Indications
|
|
|
|
|
|
|
|
|
|
|
|
Marco A. Passini,
Genzyme Corporation
Gene and Antisense Oligonucleotide Therapies for Spinal Muscular Atrophy
|
|
|
John Chaddock,
Syntaxin Ltd
Short Talk: Clostridial Endopeptidases - A Novel Platform for Therapeutic Proteins
|
|
|
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Grindelwald/Davos
|
|
8:00 - 11:00 PM
|
Entertainment
|
Grindelwald/Davos
|
| Wednesday, January 13 |
|
|
Departure
|
|
